M. Khorsand

A Phase Ib / II Trial of Granulocyte-Macrophage 2 Colony Stimulating Factor and Interleukin-2 for Renal Cell Carcinoma Patients with Pulmonary Metastases

G. Wilding, KyungMann Kim, J. Schiller, 2000 .

Phase IB trial of chimeric antidisialoganglioside antibody plus interleukin 2 for melanoma patients.

R. Bechhofer, B. Storer, J. Schiller, 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase II trial of oral piritrexim in advanced, previously treated transitional cell cancer of bladder

G. Wilding, M. Collier, L. Feun, 2004, Investigational New Drugs.

Central venous device‐related infection and thrombosis in patients treated with moderate dose continuous‐infusion interleukin‐2

KyungMann Kim, J. Schiller, D. Maki, 2001, Cancer.

Distinct clinical and laboratory activity of two recombinant interleukin-2 preparations.

M. Lindstrom, J. Schiller, M. Albertini, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

A Phase Ib/II trial of granulocyte‐macrophage−colony stimulating factor and interleukin‐2 for renal cell carcinoma patients with pulmonary metastases

G. Wilding, J. Schiller, M. Albertini, 2000, Cancer.

Clinical and immunological effects of granulocyte-macrophage colony-stimulating factor coadministered with interleukin 2: a phase IB study.

B. Storer, G. Wilding, J. Schiller, 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.